EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer

Hongyan Gou, Chi Chun Wong, Huarong Chen, Haiyun Shang, Hao Su, Jianning Zhai, Weixin Liu, Wenxiu Liu, Donglei Sun, Xin Wang, Jun Yu

Cancer Letters · 2023-12 · 578 · 216438

DOI: 10.1016/j.canlet.2023.216438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2023-12. Verfasst von Hongyan Gou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Healt…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastasis is the primary cause of death in colorectal cancer (CRC). Thyroid hormone receptor interacting protein 6 (TRIP6) is an adaptor protein that regulates cell motility. Here, we aim to elucidate the role of TRIP6 in driving CRC tumorigenesis and metastasis and evaluate its potential as a therapeutic target. TRIP6 mRNA is up-regulated in CRC compared to adjacent normal tissues in three independent cohorts (all P < 0.0001), especially in liver metastases (P < 0.001). High TRIP6 expression predicts poor prognosis of CRC patients in our cohort (P = 0.01) and TCGA cohort (P = 0.02). Colon-specific TRIP6 overexpression (Trip6KIVillin-Cre) in mice accelerated azoxymethane (AOM)-induced CRC (P < 0.05) and submucosal invasion (P < 0.0001). In contrast, TRIP6 knockout (Trip6+/- mice) slowed tumorigenesis (P < 0.05). Consistently, TRIP6 overexpression in CRC cells promoted epithelial-mesenchymal transition (EMT), cell migration/invasion in vitro, and metastases in vivo (all P < 0.05), whereas knockdown of TRIP6 exerted opposite phenotypes. Mechanistically, TRIP6 interacted PDZ domain-containing proteins such as PARD3 to impair tight junctions, evidenced by decreased tight junction markers and gut permeability dysfunction, inhibit PTEN, and activate oncogenic Akt signaling. TRIP6-induced pro-metastatic phenotypes and Akt activation depends on PARD3. Targeting TRIP6 by VNP-encapsulated TRIP6-siRNA synergized with Oxaliplatin and 5-Fluorouracil to suppress CRC liver metastases. In conclusion, TRIP6 promotes CRC metastasis by directly interacting with PARD3 to disrupt tight junctions and activating Akt signaling. Targeting of TRIP6 in combination with chemotherapy is a promising strategy for the treatment of metastatic CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLiver NeoplasmsAnimalsHumansMiceCarcinogenesisCell Line, TumorCell MovementCell Transformation, NeoplasticDrug ResistanceEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticNeoplasm MetastasisProto-Oncogene Proteins c-aktTight JunctionsTranscription FactorsAdaptor Proteins, Signal TransducingLIM Domain Proteins

Stichwörter der Autor:innen

ChemotherapyColorectal cancerEpithelial-mesenchymal transitionTRIP6Tight junction

Substanzen

Proto-Oncogene Proteins c-aktTranscription FactorsTRIP6 protein, humanAdaptor Proteins, Signal TransducingLIM Domain ProteinsTrip6 protein, mouse

Autor:innen und Institutionen

  • Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University o…
  • Department of Pathology, The First Hospital of Hebei Medical University, Hebei, China.

Zitieren

APA

Gou, H., Wong, C. C., Chen, H., Shang, H., Su, H., Zhai, J., Liu, W., Liu, W., Sun, D., Wang, X., & Yu, J. (2023). TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer. Cancer Letters, 578, 216438. https://doi.org/10.1016/j.canlet.2023.216438

Vancouver

Gou H, Wong CC, Chen H, Shang H, Su H, Zhai J, et al. TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer. Cancer Letters. 2023;578:216438. doi:10.1016/j.canlet.2023.216438

BibTeX
@article{Gou2023,
  author = {Gou, Hongyan and Wong, Chi Chun and Chen, Huarong and Shang, Haiyun and Su, Hao and Zhai, Jianning and Liu, Weixin and Liu, Wenxiu and Sun, Donglei and Wang, Xin and Yu, Jun},
  title = {TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer},
  journal = {Cancer Letters},
  year = {2023},
  volume = {578},
  pages = {216438},
  doi = {10.1016/j.canlet.2023.216438}
}
Kostenlos starten →